Camcevi (leuprorelin)
- Region
- 🇪🇺 EU
- Active substance
- leuprorelin
- Company
- Accord Healthcare S.L.U.
- Status
- Authorised
- Therapeutic area
- Prostatic Neoplasms
- CHMP opinion
- Thu 24 Mar 2022
- EU approval
- Tue 24 May 2022
- Application
- EMEA/H/C/005034
- Official record
- www.ema.europa.eu
Indication
Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Camcevi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.